Nanobodies as novel agents for cancer therapy

Expert Opinion on Biological Therapy

Volumn 5, Issue 1, 2005, Pages 111-124

  Revets, Hilde ^a   De Baetselier, Patrick ^a   Muyldermans, Serge ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Camels; Cancer therapy; Heavy chain antibodies; Llama; Nanobody; Single domain antibody; VHH

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CROFAB; DACLIZUMAB; DIGOXIN ANTIBODY F(AB) FRAGMENT; EDRECOLOMAB; EFALIZUMAB; EPITOPE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY; INFLIXIMAB; NANOBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; BIOPHYSICS; CANCER; CANCER THERAPY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; HEAVY CHAIN; IMMUNOGENICITY; MOLECULAR CLONING; MOLECULAR SIZE; NONHUMAN; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS;

CAMELIDAE; LAMA GLAMA;

EID: 12244264821     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.1.111     Document Type: Review

References (137)

1. KÖHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
2. BERARD JL: A review of interleukin-2 receptor antagonists in solid organ transplantations. Pharmacotherapy (1999) 19:1127-1137.
3. HENRY ML, RAJAB A: The use of basiliximab in solid organ transplantation. Expert Opin. Pharmacother. (2002) 3:1657-1663.
4. PANKHURST T, ADU D: Antibodies in the prevention of renal allograft rejection. Expert Opin. Biol. Ther. (2004) 4:243-252.
5. SANDBOM WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm. Bowel Dis. (1999) 5:119-133.
6. O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2591-2602.
7. PANACCIONE R, FEDORAK RN, AUMAIS G et al.: Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can. J. Gastroenterol. (2004) 18:503-508.
8. SAEZ-LLORENS X, CASTANO E, NULL D: Safety and pharmacokinetics of an intramuscular humanised antibody monoclonal antibody to respiratory syncitial virus in premature infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. (1998) 17:787-791.
9. GROOTHUIS JR, NISHIDA H: Prevention of respiratory syncitial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr. Int. (2002) 44:235-241.
10. BURTON DR: Antibodies, viruses and vaccines. Nat. Rev. Immunol. (2002) 2:706-713.
11. HULS GA, HEIJNEN IA, CUOMO ME et al.: A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat. Biotechnol. (1999) 17:276-280.
12. FARAH RA, CLINCHY B, HERRERA L, VITETTA ES: The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukaryot. Gene Expr. (1998) 8:321-356.
13. CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129.
14. GURA T: Therapeutic antibodies: magic bullets hit the target. Nature (2002) 417:584-586.
15. KHAZAELI MB, CONRY RM, LOBUGLIO AF: Human response to monoclonal antibodies. J. Immunother. (1994) 15:42-52.
16. PENDLEY G, SCHANTZ A, WAGNER C: Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. (2003) 5:172-179.
17. MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 21:6851-6855.
18. RIECHMANN L, CLARK M, WALDMANN H et al.: Reshaping human antibodies for therapy. Nature (1988) 332:323-327.
19. GREEN LL: Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods (1999) 231:11-23.
20. HULS G, HEIJNEN IA, CUOMO E: Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. (1999) 59:5778-5784.
21. PRESTA LG: Engineering antibodies for therapy. Curr. Pharm. Biotechnol. (2002) 3:237-256.
22. WEIR AN, NESBITT A, CHAPMAN AP, POPPLEWELL AG, ANTONIW P, LAWSON AD: Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. (2002) 30:512-516.
23. CHOY EH, HAZLEMAN B, SMITH M: Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (2002) 41:1133-1137.
24. WINTER G, MILSTEIN C: Man-made antibodies. Nature (1991) 349:293-299.
25. WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOM HR: Making antibodies by phage display technology. Annu. Rev. Immunol. (1994) 12:433-455.
26. BETTER M, CHANG CP, ROBINSON RR, HORWITZ AH: Escherichia coli secretion of an active chimeric antibody. Science (1988) 240:1041-1043.
27. FRENKEN L, HESSING JG, VAN DEN HONDEL CA, VERRIPS CT: Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res. Immunol. (1998) 149:589-598.
28. ADAMS GP, SCHIER R, MCCALL AM: High affinity restricts the localisation and tumor penetration of single-chain Fv antibody molecules. Cancer Res. (2001) 61:4750-4755.
29. WU AM, YAZAKI PJ: Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. (2000) 44:268-283.
30. YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1990) 52:3402-3408.
31. HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9:139-134.
32. NIELSEN UB, ADAMS GP, WEINER LM, MARKS JD: Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. (2000) 60:6434-6440.
33. HUDSON PJ, SOURIAU C: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. (2001) 1:845-855.
34. TODOROVSKA A, ROOVERS RC, DOLEZAL O: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods (2001) 248:47-66.
35. WILLUDA J, HONEGGER A, WAIBEL R et al.: High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized antiepithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. (1999) 59:5758-5767.
36. WHITLOW M, BELL BA, FENG SL et al.: An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. (1993) 6:989-995.
37. WARD ES, GÜSSOW DH, GRIFFITHS AD, JONES PT, WINTER G: Binding activities of a single immunoglobulin variable domain secreted from E. coli. Nature (1989) 341:544-546. First report on the possibility of obtaining single-domain antibody fragments from immunised mice.
38. BORREBAECK CAK, MALMBORG AC, FUREBRING C et al.: Kinetic analysis of recombinant antibody-antigen interactions: relation between structural domains and antigen binding. Biotechnology (1992) 10:697-698.
39. JESPERS L, SCHON O, FAMM K, WlNTER G: Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. (2004) 22:1161-1165.
40. HAMERS-CASTERMAN C, ATARHOUCH T, MUYLDERMANS S et al.: Naturally occurring antibodies devoid of light chains. Nature (1993) 363:446-448. First report on the occurrence of HCAbs in camelids.
41. ORLANDI R, GÜSSOW DH, JONES PT, WINTER G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA (1989) 86:3833-3837.
42. NGUYEN VK, HAMERS R, WYNS L, MUYLDERMANS S: Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IgG2a heavy-chain antibodies. Mol. Immunol. (1999) 36:515-524.
43. WOOLVEN BP, FRENKEN LG, VAN DER LOGT P, NICHOLLS PJ: The structure of the llama heavy-chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics (1999) 50:98-101.
44. PADLAN EA: Anatomy of the antibody molecule. Mol. Immunol. (1994) 31:169-217.
45. DESMYTER A, TRANSUE TR, ARBABI-GHAHROUDI M et al.: Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. (1996) 3:803-811. First description of the structure of a nanobody in complex with its target.
46. SPINELLI S, FRENKEN L, BOURGEOIS D et al.: The crystal structure of the llama heavy chain variable domain. Nat. Struct. Biol. (1996) 3:752-757.
47. DECANNIERE K, DESMYTER A, LAUWEREYS M, GHAROUDI MA, MUYLDERMANS S, WYNS L: A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Struct. Fold. Des. (1999) 7:361-370.
48. RENISIO JG, ROMI-LEBRUN R, BLANC E: Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from llama. Prot. Struct. Funct. Genet. (2002) 47:546-555.
49. VRANKEN W, TOLKATCHEV D, XU P: Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface. Biochemistry (2002) 41:8570-8579.
50. DECANNIERE K, MUYLDERMANS S, WYNS L: Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes? J. Mol. Biol. (2000) 300:83-91.
51. VU KB, GHARHOUDI MA, WYNS L, MUYLDERMANS S: Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol. Immunol. (1997) 34:1121-1131.
52. NGUYEN VK, HAMERS R, WYNS L, MUYLDERMANS S: Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. (2000) 19:921-931. Description of the mechanisms involved in enlarging the antigen-binding repertoire of nanobodies.
53. MUYLDERMANS S, CAMBILLAU C, WYNS L: Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. (2001) 26:230-235.
54. WU TT, JOHNSON G, KABAT EA: Length distribution of CDRH3 in antibodies. Proteins (1993) 16:1-7.
55. HARMSEN MM, RUULS RC, NIJMAN IJ, NIEWOLD TA, FRENKEN LG, DE GEUS B: Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. (2000) 37:579-590.
56. MUYLDERMANS S, ATARHOUCH T, SALDHANA J, BARBOSA JA, HAMERS R: Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. (1994) 7:1129-1135.
57. KABAT E, WU TT, PERRY HM, GOTTESMAN KS, FOELLER C: Sequence of Proteins of Immunological Interest. (1991). US Public Health Services, NIH Bethesda, MD, Publication No. 91.
58. RIECHMANN L, MUYLDERMANS S: Single-domain antibodies: comparison of camel VH and camdised human VH domains. J. Immunol. Methods (1999) 231:25-38.
59. DAVIES J, RIECHMANN L: 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett. (1994) 339:285-290. First description of 'camelisation' of human antibody fragments.
60. KORTT AA, GUTHRIE RE, HINDS MG: Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41. J. Protein Chem. (1995) 14:167-178.
61. DAVIES J, RIECHMANN L: Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. (1996) 9:531-537.
62. MARTIN F, VOLPARI C, STEIKÜHLER C et al.: Affinity selection of a camelised VH domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. (1997) 10:607-614.
63. VOORDIJK S, HANSSON T, HILVERT D, VAN GUNSTEREN WF: Molecular dynamics simulations highlight mobile regions in proteins: a novel suggestion for converting a murine VH domain into a more tractable species. J. Mol. Biol. (2000) 300:963-973.
64. RIECHMANN L: Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain. J. Mol. Biol. (1996) 259:957-969.
65. TANHA J, XU P, CHEN Z et al.: Optimal design features of camelised human single-domain antibody libraries. J. Biol. Chem. (2001) 276:24774-24780.
66. EWERT S, CAMBILLAU C, CONRATH K, PLUCKTHUN A: Biophysical properties of camelid VHH domains compared to those of human VH3 domains. Biochemistry (2002) 41:3628-3636.
67. EWERT S, HUBER T, HONEGGER A, PLUCKTHUN A: Biophysical properties of human antibody variable domains. J. Mol. Biol. (2003) 325:531-553.
68. AIRES DA SILVA F, SANTA-MARTA M, FREITAS-VIEIRA A et al.: Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J. Mol. Biol. (2004) 340:525-542.
69. GREENBERG AS, AVILA D, HUGHES M, HUGHES A, MCKINNEY EC, FLAJNIK MF: A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature (1995) 374:168-173.
70. STANFIELD RL, DOOLEY H, FLAJNIK MF, WILSON IA: Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science (2004) 305:1770-1773.
71. STRELTSOV VA, VARGHESE JN, CARMICHAEL JA, IRVING RA, HUDSON PJ, NUTTALL SD: Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc. Natl. Acad. Sci. USA (2004) 101:12444-12449.
72. HUFTON SE, VAN NEER N, VAN DEN BEUKEN T, DESMET J, SABLON E, HOOGENBOOM HR: Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Lett. (2000) 475:225-231.
73. KARATAN E, MERGUERIAN M, HAN Z, SCHOLLE MD, KOIDE S, KAY BK: Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem. Biol (2004) 11:835-844.
74. KOIDE A, BAILEY CW, HUANG X, KOIDE S: The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. (1998) 284:1141-1151.
75. HOOGENBOOM HR, DE BRUINE A, HUFTON SE, HOET RM, ARENDS JW, ROOVERS RC: Antibody phage display technology and its applications. Immunotechnology (1998) 4:309-318.
76. GHARHOUDI MA, DESMYTER A, WYNS L, HAMERS R, MUYLDERMANS S: Selection and identification of single-domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. (1997) 414:521-526.
77. LAUWEREYS M, GHARHOUDI MA, DESMYTER A et al.: Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. (1998) 17:3512-3520. First report of nanobodies as enzyme inhibitors.
78. CORTEZ-RETAMOZO V, BACKMANN N, SENTER P et al.: Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. (2004) 64:2853-2857. First report describing the efficiency of nanobodies as cancer therapeutics.
79. FRENKEN L, HESSING JG, VAN DEN HONDEL CA, VERRIPS CT: Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res. Immunol. (1998) 149:589-598.
80. REITER Y, SCHUCK P, BOYD LF, PLASKIN D: An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J. Mol. Biol. (1999) 290:685-698.
81. YAU KY, GROVES MA, LI S et al.: Selection of hapten-specific single domain antibodies from a non-immunized llama ribosome display library. J. Immunol. Methods (2003) 281:161-175.
82. HAWKINS RE, RUSSELL SJ, WINTER G: Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. (1992) 226:889-896.
83. MARKS JD, GRIFFITHS AD, MALMQVIST M, CLACKSON TP, BYE JM, WINTER G: By-passing immunisation: building high affinity human antibodies by chain shuffling. Biotechnology (1992) 10:779-783.
84. LOW NM, HOLLIGER PH, WINTER G: Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. (1996) 260:359-368.
85. JOOSTEN V, LOKMAN C, VAN DEN HONDEL CA, PUNT PJ: The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb. Cell Fact. (2003) 2:1.
86. FRENKEN L, VAN DER LINDEN RH, HERMANS PW et al.: Isolation of antigen-specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. (2000) 78:11-21.
87. VAN DER VAART JM: Expression of VHH antibody fragments in Saccharomyces cerevisiae. Methods Mol. Biol. (2002) 178:359-366.
88. VAN DER LINDEN RH, DE GEUS B, FRENKEN GJ, PETERS H, VERRIPS CT: Improved production and function of llama heavy chain antibody fragments by molecular evolution. J. Biotechnol. (2000) 80:261-270.
89. VAN DER LINDEN RH, FRENKEN LG, DE GEUS B et al.: Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochem. Biophys. Acta (1999) 1431:37-46.
90. PEREZ JM, ENISIO JG, PROMPERS JJ et al.: Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry (2001) 40:74-83.
91. DUMOULIN M, CONRATH K, VAN MEIRHAEGHE A et al.: Single-domain antibody fragments with high conformational stability. Protein Sci. (2002) 11:500-515.
92. WORN A, PLÜCKTHUN A: Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. (2001) 305:989-1010.
93. EWERT S, HONEGGER A, PLUCKTHUN A: Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalisable approach. Biochemistry (2003) 42:1517-1528.
94. SPINELLI S, FRENKEN LG, HERMANS P et al.: Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry (2000) 39:1217-1222. First crystal structure of a nanobody in complex with its cognate hapten.
95. SPINELLI S, TEGONI M, FRENKEN L, VAN VLIET C, CAMBILLAU C: Lateral recognition of a dye hapten by a llama VHH domain. J. Mol. Biol. (2001) 311:123-129.
96. RAHBARIZADEH F, RASAEE MJ, MOGHADAM FM, ALLAMEH AA, SADRODDINY E: Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid. Hybridomics (2004) 23:151-159.
97. LEDEBOER AM, BEZEMER S, DE HAARD JJ et al.: Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. J. Dairy Sci. (2002) 85:1376-1382.
98. STIJLEMANS B, CONRATH K, CORTEZ-RETAMOZO V et al.: Efficient targeting of conserved cryptic epitopes of infectious agents by single-domain antibodies. African trypanosomes as a paradigm. J. Biol. Chem. (2004) 279:1256-1261. First report on nanobodies recognising cryptic epitopes.
99. LASKOWSKI RA, LUSCOMBE NM, SWINDELLS MB, THORNTON JM: Protein clefts in molecular recognition and function. Protein Sci. (1996) 5:2438-2452.
100. WEBSTER DM, HENRY AH, REES AR: Antibody-antigen interactions. Curr. Opin. Struct. Biol. (1994) 4:123-129.
101. PADLAN EA: X-ray crystallography of antibodies. Adv. Protein Chem. (1996) 49:57-133.
102. TRANSUE TR, DE GENST E, GHARHOUDI MA, WYNS L, MUYLDERMANS S: Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Prot. Struct. Funct. Genet. (1998) 32:515-522.
103. DESMYTER A, SPINELLI S, PAYAN F, LAUWEREYS M, WYNS L, MUYLDERMANS S: Three camelid VHH domains in complex with porcine pancreatic alpha amylase. Inhibition and versatility of binding topology. J. Biol. Chem. (2002) 277:23645-23650.
104. ROBERT B, DORVILLIUS M, BUCHEGGER F: Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int. J. Cancer (1999) 81:285-291.
105. SEGAL DM, WEINER GJ, WEINER LM: Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. (1999) 11:558-562.
106. HUDSON P, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 1:129-134.
107. KIPRIYANOV SM: Generation of bispecific and tandem diabodies. Methods Mol. Biol. (2002) 178:317-331.
108. CONRATH K, LAUWEREYS M, WYNS L, MUYLDERMANS S: Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. (2001) 276:7346-7350.
109. ZHANG J, TANHA J, HIRAMA T et al.: Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J. Mol. Biol. (2004) 335:49-56.
110. PLESCHBERGER M, SAERENS D, WEIGERT S, SLEYTR UB, MUYLDERMANS S, SARA M: An S-layer heavy chain camel antibody fusion protein for generating of a nanopatterned sensing layer to detect the prostate specific antigen by surface plasmon resonance technique. Bioconjug. Chem. (2004) 15:664-671.
111. PLESCHBERGER M, NEUBAUER A, EGELSEER EM et a.: Generation of a functional mononuclear protein lattice consisting of an S-layer fusion protein comprising the variable domain of a camel heavy-chain antibody. Bioconjug. Chem. (2003) 14:440-448.
112. DUMOULIN M, LAST AM, DESMYTER A et al.: A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 424:783-788. First report of nanobodies interfering with fibril formation.
113. LORIS R, MARIANOVSKY I, LAH J et al.: Crystal structure of the intrinsically flexible addiction antidote MazE. J. Biol. Chem. (2003) 278:28252-28257.
114. VAN KONINGSBRUGGEN S, DE HAARD H, DE KIEVIT P et al.: Llama derived phage display antibodies in the dissection of the human disease oculapharyngeal muscular dystrophy. J. Immunol. Methods (2003) 279:149-161.
115. JOBLING AS, JARMAN C, TEH MM, HOLMBERG N, BLAKE C, VERHOEYEN ME: Immunomodulation of enzyme function in plants by single-domain antibodies. Nat. Biotechnol. (2003) 21:77-80. First description of a nanobody as an intrabody.
116. CONRATH KE, WERNERY U, MUYLDERMANS S, NGUYEN VK: Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev. Comp. Immunol. (2003) 27:87-103.
117. DEKKER S, TOUSSAINT W, PANAYOTOU G et al.: Intracellularly expressed single domain antibody against p15 matrix protein prevents the production of porcine retroviruses. J. Virol. (2003) 77:12132-12139.
118. KONTERMAN RE: Intrabodies as therapeutic agents. Methods (2004) 34:163-170.
119. AUF DER MAUR A, ESCHER D, BARBERIS A: Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett. (2001) 508:407-412.
120. VISINTIN M, QUONDAM M, CATTANEO A: The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. (2002) 317:73-83.
121. ROSEBROUGH SF: Two-step immunological approaches for imaging and therapy. Q. J. Nucl. Med. (1996) 40:234-251.
122. ZUCKIER LS, DENARDO GL: Trials and tribulations: oncological antibody imaging comes to the fore. Semin. Nucl. Med. (1997) 27:10-29.
123. 124I-labeled engineered anti-CEA minibodies and diabodies allow high contrast, antigen-specific small-animal PET imaging of xenografts in mice. J. Nucl. Med. (2003) 44:1962-1969.
124. CORTEZ-RETAMOZO V, LAUWEREYS M, HASSANZADEH GH et al.: Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer (2002) 98:456-462. First report describing the tumour-targeting properties of nanobodies.
125. WAIBEL R, ALBERTO R, WILLUDA J et al.: Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. (1999) 17:897-901.
126. NIKOLAJCZYK SD, CATALONA WJ, EVANS CL et al.: Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. (2004) 50:1017-1025.
127. SAERENS D, KINNE J, BOSMANS E, WERNERY U, MUYLDERMANS S, CONRATH K: Single-domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. (2004) 279(50):51965-51972.
128. PAWELEK JM, BROOKS KL, BERMUDES D: Bacteria as tumor-targeting vectors. Lancet Oncol. (2003) 4:548-556.
129. VEIGA E, DELORENZO V, FERNANDEZ LA: Structural tolerance of bacterial autotransporters for folded passenger protein domains. Mol. Microbiol. (2004) 52:1069-1080.
130. MURUGANANDAM A, TANHA J, NARANG S, STANIMIROVIC D: Selection of phage-displayed llama single-chain domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. (2001) 16(2):240-242. First description of a nanobody crossing the BBB.
131. CHAPMAN AP: PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. (2002) 54:531-545.
132. BENDER E, WOOF JM, ATKIN JD, BARKER MD, BEBBINGTON CR, BURTON DR: Recombinant human antibodies: linkage of a Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Hum. Antibodies Hybridomas (1993) 4:74-79.
133. SMITH BJ, POPPLEWELL A, ATHWAL D et al.: Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug. Chem. (2001) 12:750-756.
134. JUNGHANS RP: Finally! The Brambell receptor (FcRB): mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. (1997) 16:29-57.
135. CHAUDHURY C, MEHNAZ S, ROBINSON JM et al.: The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. (2003) 197:315-322.
136. DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35035-35043.
137. TANHA J, DUBUC G, HIRAMA T, NARANG SA, MACKENZIE CR: Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J. Immunol. Methods (2002) 263:97-109.